Archon Bio is a biotechnology company developing geometrically tunable protein therapeutics that target pathways other technologies cannot. The company is recognized for its innovation in computationally designed biologics.

Archon Bio

Archon Biosciences | 1,193 followers on LinkedIn. Pioneering next-generation antibody therapies with AI and computational protein design  | Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.  

We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Senior Associate Scientist at Archon Bio

Justin Hare

Sr. Scientist, Immunology

Christie Mortales

Head of Research

Jonathan Graves

Senior Scientist - Biology Lead

Justin Huard

Archon Biosciences

Although we emerged from stealth yesterday, our technology and vision has been developed for over a decade. Beyond innovative science, great biotechs are built on great relationships. We wouldn’t be here today without Madrona ’s conviction and belief in us since day one. Their leadership in AI-driven biotech and commitment to the transformational potential of Antibody Cages (AbCs) have enabled Archon to become a reality. We’re excited to continue this partnership and apply generative protein design to build best-in-class medicines together!

Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development! We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines. Learn more in our press release here: https://lnkd.in/eTJxYNuk To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/ #biotech #antibodies #AI #ComputationalProteinDesign #AbC

Metric
Company Name	Archon Bio
Symbol
MSH ID	BIO:ARCHON
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	archon.bio
LinkedIn	archonbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ARCH

BIO:ARCHON

Archon Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue